Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1919 1
1920 1
1925 2
1936 2
1942 1
1952 1
1958 1
1959 1
1961 3
1963 3
1964 5
1966 5
1967 2
1968 1
1969 1
1970 5
1971 3
1972 5
1973 3
1974 4
1975 7
1976 9
1977 8
1978 3
1979 11
1980 6
1981 9
1982 9
1983 6
1984 10
1985 9
1986 5
1987 2
1988 7
1989 6
1990 6
1991 7
1992 5
1993 2
1994 4
1995 8
1996 8
1997 14
1998 16
1999 14
2000 17
2001 9
2002 19
2003 12
2004 24
2005 26
2006 28
2007 37
2008 54
2009 84
2010 87
2011 64
2012 89
2013 98
2014 116
2015 136
2016 117
2017 164
2018 127
2019 132
2020 141
2021 184
2022 225
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

2,030 results
Results by year
Filters applied: . Clear all
Page 1
Single-cell epigenomic analyses implicate candidate causal variants at inherited risk loci for Alzheimer's and Parkinson's diseases.
Corces MR, Shcherbina A, Kundu S, Gloudemans MJ, Frésard L, Granja JM, Louie BH, Eulalio T, Shams S, Bagdatli ST, Mumbach MR, Liu B, Montine KS, Greenleaf WJ, Kundaje A, Montgomery SB, Chang HY, Montine TJ. Corces MR, et al. Among authors: kundu s. Nat Genet. 2020 Nov;52(11):1158-1168. doi: 10.1038/s41588-020-00721-x. Epub 2020 Oct 26. Nat Genet. 2020. PMID: 33106633 Free PMC article.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW, Gooderham M, Warren RB, Papp KA, Strober B, Thaçi D, Morita A, Szepietowski JC, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Armstrong AW, et al. Among authors: kundu s. J Am Acad Dermatol. 2022 Jul 9:S0190-9622(22)02256-3. doi: 10.1016/j.jaad.2022.07.002. Online ahead of print. J Am Acad Dermatol. 2022. PMID: 35820547 Free article.
Role of Insulin in Health and Disease: An Update.
Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, Hannan MA, Uddin MJ, Pang MG. Rahman MS, et al. Among authors: kundu s. Int J Mol Sci. 2021 Jun 15;22(12):6403. doi: 10.3390/ijms22126403. Int J Mol Sci. 2021. PMID: 34203830 Free PMC article. Review.
Preface.
Caballero D, Kundu SC, Reis RL. Caballero D, et al. Among authors: kundu sc. Methods Cell Biol. 2020;157:xv. doi: 10.1016/S0091-679X(20)30085-6. Methods Cell Biol. 2020. PMID: 32334723 No abstract available.
MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects.
Verma V, Jafarzadeh N, Boi S, Kundu S, Jiang Z, Fan Y, Lopez J, Nandre R, Zeng P, Alolaqi F, Ahmad S, Gaur P, Barry ST, Valge-Archer VE, Smith PD, Banchereau J, Mkrtichyan M, Youngblood B, Rodriguez PC, Gupta S, Khleif SN. Verma V, et al. Among authors: kundu s. Nat Immunol. 2021 Jan;22(1):53-66. doi: 10.1038/s41590-020-00818-9. Epub 2020 Nov 23. Nat Immunol. 2021. PMID: 33230330
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.
Flaig TW, Spiess PE, Abern M, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chan K, Chang S, Friedlander T, Greenberg RE, Guru KA, Herr HW, Hoffman-Censits J, Kishan A, Kundu S, Lele SM, Mamtani R, Margulis V, Mian OY, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Parikh M, Patterson A, Plimack ER, Pohar KS, Preston MA, Richards K, Sexton WJ, Siefker-Radtke AO, Tollefson M, Tward J, Wright JL, Dwyer MA, Cassara CJ, Gurski LA. Flaig TW, et al. Among authors: kundu s. J Natl Compr Canc Netw. 2022 Aug;20(8):866-878. doi: 10.6004/jnccn.2022.0041. J Natl Compr Canc Netw. 2022. PMID: 35948037
Editorial Comment.
Weiner AB, Kundu SD. Weiner AB, et al. Among authors: kundu sd. J Urol. 2021 May;205(5):1284-1285. doi: 10.1097/JU.0000000000001641.02. Epub 2021 Mar 11. J Urol. 2021. PMID: 33705232 No abstract available.
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial.
Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp KA. Strober B, et al. Among authors: kundu s. J Am Acad Dermatol. 2022 Sep 14:S0190-9622(22)02643-3. doi: 10.1016/j.jaad.2022.08.061. Online ahead of print. J Am Acad Dermatol. 2022. PMID: 36115523 Free article.
Could 3D models of cancer enhance drug screening?
Brancato V, Oliveira JM, Correlo VM, Reis RL, Kundu SC. Brancato V, et al. Among authors: kundu sc. Biomaterials. 2020 Feb;232:119744. doi: 10.1016/j.biomaterials.2019.119744. Epub 2019 Dec 26. Biomaterials. 2020. PMID: 31918229 Review.
2,030 results